Last week RVX made a presentation in which the clinical estimates slide states first US patients in BETOnMACE will be randomized in Q1/18 (ie very soon) now today they are announcing that they are considering whether or not to enrol US patients.  What changed in the last few days?  Contradictory statements like this along with management’s failure to put this company on secure financial footing will not inspire any confidence in the market that is for certain.  This in turn means further unfavourable financings.  What a gong show.